Potential Promise for PD-1 Blockade Seen in Sarcoma SubtypesFebruary 6th 2017
Several subtypes of difficult-to-treat sarcomas may respond to treatment with PD-1 pathway inhibiting immunotherapies, according to findings of an immunohistochemistry analysis of a large patient population.
Immunotherapy Will Play a Critical Role in Osteosarcoma Treatment, Expert SaysDecember 29th 2016
Nancy Gordon, MD, speaks about her osteosarcoma research, the next steps following the findings of the study, and what she envisions for the treatment landscape of osteosarcoma over the next decade.
New Agents, Targets Continue to Emerge in Sarcoma, Cementing Role for ImmunotherapyNovember 29th 2016
Breelyn Wilky, MD, recently sat down <em>Targeted Oncology</em> to discuss recent findings of a trial investigating axitanib and pembrolizumab in soft tissue sarcomas, as well as the role she envisions for immunotherapy in the treatment of sarcoma.
Limb Function Not Improved by Lower Volume Radiation for Extremity STSNovember 19th 2016
A lower dose of radiation therapy following surgery did not improve limb function and was not found to be non-inferior compared with standard dose radiation 2 years post procedure in patients extremity soft tissue sarcoma.
TRC105 Plus Pazopanib Shows Promise in Advanced AngiosarcomaNovember 13th 2016
TRC105, an endoglin antibody, combined with pazopanib showed promising anti-tumor activity in patients with advanced angiosarcoma, warranting the initiation of a phase III study to explore the combination further.<br />
Radiomics Could Play Important Predictive Role in Patient Outcomes in SarcomaNovember 12th 2016
Though surgical resection and radiation therapy remain at the forefront of the treatment for localized disease, accurately predicting outcomes for individual patients remains a challenge, which radiomics, an emerging research field, hopes to alleviate.
Model Suggests Olaratumab May Be Effective in Pediatric SarcomaNovember 12th 2016
Olaratumab displayed anti-tumor activity both as a single-agent and in concert with standard of care chemotherapy in a study using human pediatric sarcoma cell-derived models and in human sarcoma cell transfected mice.
Pembrolizumab Plus Cyclophosphamide Shows Limited Benefit in Diverse Types of SarcomaNovember 12th 2016
Pembrolizumab plus low dose metronomic cyclophosphamide demonstrated limited patient benefit in adult patients with diverse types of unresectable locally advanced or metastatic sarcoma.<br />
The Role of Immunotherapy in the Future Treatment Landscape of SarcomaNovember 12th 2016
Elizabeth Loggers, MD, PhD, medical oncologist, Seattle Cancer Care Alliance, discusses the role that she expects immunotherapy will play in the future treatment landscape of sarcoma.
Nivolumab/Pazopanib Combo Shows Promise in Relapsed SarcomaNovember 12th 2016
Clinical benefit, including partial response and stable disease, was observed in 11 of 20 patients with relapsed metastatic sarcoma following nivolumab treatment that was administered either alone or in combination with pazopanib.
Expert Discusses Pembrolizumab Potential in SarcomaNovember 12th 2016
Updated results of the multicenter phase II study SARC028 demonstrate both a favorable safety profile as well as encouraging efficacy for the use pembrolizumab (Keytruda) as a treatment for patients with advanced sarcomas.
Pembrolizumab Demonstrates Anti-Tumor Activity in Sarcoma SubtypesNovember 11th 2016
Treatment with pembrolizumab, an immunotherapeutic agent approved in melanoma, lung, and head and neck cancer, and which is undergoing investigation in several other cancer types, reduced the size of tumors in patients with a specific soft tissue sarcoma.
Risk of Local Recurrence Varies Across Sarcoma Histotypes With Adjuvant/Neoadjuvant TherapyNovember 11th 2016
Adjuvant chemotherapy was found to decrease the rates of local recurrence in some subtypes of extremity soft tissue sarcoma; however, the use of adjuvant/neoadjuvant therapy did not impact overall survival.
Expert Highlights Factors Influencing Local Control in Ewing SarcomaNovember 11th 2016
<br /> Local recurrence is associated with very poor prognosis in patients with Ewing sarcoma. Researchers are seeking to identify the factors associated with local recurrence in patients undergoing multimodal treatment.
David Thomas, FRACP, PhD, director and division head, Genomic Cancer Medicine, Cancer Division, Garvan Institute of Medical Research, discusses the genomic features of sarcoma and how they factor into the treatment landscape of this disease.